Patents by Inventor Samuel D. Rabkin

Samuel D. Rabkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
    Publication number: 20200345835
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: January 10, 2020
    Publication date: November 5, 2020
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Viral vectors and their use in therapeutic methods
    Patent number: 10532095
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 14, 2020
    Assignees: Catherex, Inc., Georgetown University, The General Hospital Corporation
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Use of herpes vectors for tumor therapy
    Patent number: 9827307
    Abstract: Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: November 28, 2017
    Assignee: Georgetown University
    Inventors: Samuel D. Rabkin, Masahiro Toda, Robert L. Martuza
  • VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
    Publication number: 20170290908
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: December 19, 2016
    Publication date: October 12, 2017
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Viral vectors and their use in therapeutic methods
    Patent number: 9555072
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 31, 2017
    Assignees: The General Hospital Corporation, Georgetown University, Catherex, Inc.
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
    Publication number: 20150071965
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: October 27, 2014
    Publication date: March 12, 2015
    Inventors: Paul JOHNSON, Robert L. MARTUZA, Samuel D. RABKIN, Tomoki TODO
  • Viral vectors and their use in therapeutic methods
    Patent number: 8871193
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: October 28, 2014
    Assignees: Catherex, Inc., The General Hospital Corporation, Georgetown University
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
    Publication number: 20130280299
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 24, 2013
    Inventors: Paul JOHNSON, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • USE OF HERPES VECTORS FOR TUMOR THERAPY
    Publication number: 20130224243
    Abstract: Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 29, 2013
    Inventors: Samuel D. Rabkin, Masahiro Toda, Robert L. Martuza
  • Viral vectors and their use in therapeutic methods
    Patent number: 8470577
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: June 25, 2013
    Assignees: Catherex, Inc., The General Hospital Corporation, Georgetown University
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Use of herpes vectors for tumor therapy
    Patent number: 8361978
    Abstract: Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: January 29, 2013
    Assignee: Georgetown University
    Inventors: Samuel D. Rabkin, Masahiro Toda, Robert L. Martuza
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Patent number: 8273568
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the ?34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: September 25, 2012
    Assignee: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Viral Vectors and Their Use in Therapeutic Methods
    Publication number: 20110070262
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: March 11, 2010
    Publication date: March 24, 2011
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Viral vectors and their use in therapeutic methods
    Patent number: 7749745
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: July 6, 2010
    Assignees: Georgetown University, The General Hospital Corporation, MediGene, Inc.
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • USE OF HERPES VECTORS FOR TUMOR THERAPY
    Publication number: 20090053178
    Abstract: Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 26, 2009
    Inventors: Samuel D. RABKIN, Masahiro TODA, Robert L. MARTUZA
  • Use of soluble costimulatory factor for tumor immuno-gene therapy
    Patent number: 7064111
    Abstract: A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cells and activates T-cells that are infiltrating or surrounding the tumor. A pharmaceutical composition containing such a gene is effective in tumor suppression.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: June 20, 2006
    Assignee: Georgetown University
    Inventors: Tomoki Todo, Samuel D. Rabkin, Robert L. Martuza
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Publication number: 20040228841
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the &ggr;34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Application
    Filed: March 1, 2004
    Publication date: November 18, 2004
    Applicants: Georgetown University, MARTUZA et al.
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Publication number: 20040151697
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the &ggr;34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Application
    Filed: December 31, 2003
    Publication date: August 5, 2004
    Applicant: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Replication-competent herpes simplex virus mediates destruction of neoplastic cells
    Patent number: 6699468
    Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the &ggr;34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: March 2, 2004
    Assignee: Georgetown University
    Inventors: Robert L. Martuza, Samuel D. Rabkin, Toshihiro Mineta
  • Viral vectors and their use in therapeutic methods
    Publication number: 20020187163
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: March 27, 2002
    Publication date: December 12, 2002
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo